JP7481252B2 - 標的放射線治療誘発性血管完全性を保護する方法 - Google Patents

標的放射線治療誘発性血管完全性を保護する方法 Download PDF

Info

Publication number
JP7481252B2
JP7481252B2 JP2020503928A JP2020503928A JP7481252B2 JP 7481252 B2 JP7481252 B2 JP 7481252B2 JP 2020503928 A JP2020503928 A JP 2020503928A JP 2020503928 A JP2020503928 A JP 2020503928A JP 7481252 B2 JP7481252 B2 JP 7481252B2
Authority
JP
Japan
Prior art keywords
subject
minutes
composition
radiation therapy
tpo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020503928A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020528903A5 (https=
JP2020528903A (ja
Inventor
エイチェンバウム，ゲリー
トネリ，アルフレッド
Original Assignee
ヤンセン ファーマシューティカ エヌ．ベー．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ヤンセン ファーマシューティカ エヌ．ベー． filed Critical ヤンセン ファーマシューティカ エヌ．ベー．
Publication of JP2020528903A publication Critical patent/JP2020528903A/ja
Publication of JP2020528903A5 publication Critical patent/JP2020528903A5/ja
Application granted granted Critical
Publication of JP7481252B2 publication Critical patent/JP7481252B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/196—Thrombopoietin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A61N2005/1092—Details
    • A61N2005/1094—Shielding, protecting against radiation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Radiology & Medical Imaging (AREA)
  • Pathology (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Radiation-Therapy Devices (AREA)
JP2020503928A 2017-07-26 2018-07-26 標的放射線治療誘発性血管完全性を保護する方法 Active JP7481252B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762537049P 2017-07-26 2017-07-26
US62/537,049 2017-07-26
PCT/US2018/043821 WO2019023418A1 (en) 2017-07-26 2018-07-26 METHODS FOR PROTECTING VASCULAR INTEGRITY INDUCED BY TARGETED RADIOTHERAPY

Publications (3)

Publication Number Publication Date
JP2020528903A JP2020528903A (ja) 2020-10-01
JP2020528903A5 JP2020528903A5 (https=) 2021-08-19
JP7481252B2 true JP7481252B2 (ja) 2024-05-10

Family

ID=63165522

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020503928A Active JP7481252B2 (ja) 2017-07-26 2018-07-26 標的放射線治療誘発性血管完全性を保護する方法

Country Status (11)

Country Link
US (1) US12251424B2 (https=)
EP (1) EP3658191A1 (https=)
JP (1) JP7481252B2 (https=)
KR (1) KR102688415B1 (https=)
CN (1) CN111432845B (https=)
AU (1) AU2018306329B8 (https=)
BR (1) BR112020001367A2 (https=)
CA (1) CA3070442A1 (https=)
IL (1) IL272213A (https=)
PH (1) PH12020500166A1 (https=)
WO (1) WO2019023418A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2021008943A (es) * 2019-01-25 2021-11-04 Janssen Pharmaceutica Nv Metodos para mitigar la lesion hepatica y promover la hipertrofia hepatica, la regeneracion e injerto celular en conjunto con tratamientos de radiacion y/o radiomimeticos.
CN113402614A (zh) * 2021-04-22 2021-09-17 山东泉港药业有限公司 血小板生成素拟肽融合蛋白(fc-tmp)编码基因与应用
CN119654158A (zh) * 2022-05-20 2025-03-18 詹森药业有限公司 用于减轻与暴露于辐射和/或辐射或拟辐射治疗相关的肺损伤的方法
WO2024095178A1 (en) 2022-11-01 2024-05-10 Janssen Pharmaceutica Nv Thrombopoietin mimetic for use in the treatment of acute liver failure
WO2025002113A1 (zh) * 2023-06-26 2025-01-02 上海济煜医药科技有限公司 一种人血小板生成素受体激动剂的融合蛋白

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001505898A (ja) 1996-12-11 2001-05-08 グラクソ、グループ、リミテッド レセプターに結合するペプチドおよび化合物
JP2007504132A (ja) 2003-08-28 2007-03-01 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド 受容体に結合するペプチドおよび化合物
WO2007087428A2 (en) 2006-01-25 2007-08-02 Amgen Inc. Thrombopoietic compounds
US20080119384A1 (en) 2004-08-16 2008-05-22 Yurkow Edward J Use of TPO peptide compounds and pharmaceutical compostions in the treatment of anemia
JP2012518408A (ja) 2009-02-24 2012-08-16 アレクシオン ファーマシューティカルズ， インコーポレイテッド 治療用ｔｐｏ／ｅｐｏ模倣ペプチドを含む抗体
JP2014097958A (ja) 2012-11-15 2014-05-29 Hirosaki Univ 放射線被ばく治療剤及び放射線被ばく治療方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU680422B2 (en) 1992-06-11 1997-07-31 Alkermes Controlled Therapeutics, Inc. Erythropoietin drug delivery system
US5354934A (en) 1993-02-04 1994-10-11 Amgen Inc. Pulmonary administration of erythropoietin
US6083913A (en) * 1995-06-07 2000-07-04 Glaxo Wellcome Inc. Peptides and compounds that bind to a thrombopoietin receptor
US7091311B2 (en) 1996-06-07 2006-08-15 Smithkline Beecham Corporation Peptides and compounds that bind to a receptor
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
ES2781475T3 (es) 2002-09-18 2020-09-02 Janssen Pharmaceuticals Inc Métodos para aumentar la producción de células madre hematopoyéticas y plaquetas
US7723295B2 (en) 2003-08-28 2010-05-25 Ortho-Mcneil Pharmaceutical, Inc. Peptides and compounds that bind to a receptor
US20060210542A1 (en) 2004-08-16 2006-09-21 Yurkow Edward J Use of TPO mimetic compounds and pharmaceutical compositions in the treatment of anemia
DK1984014T3 (da) 2006-02-14 2014-09-15 Janssen Pharmaceutica Nv Anvendelse af tpo-peptidforbindelser og farmaceutiske sammensætninger ved behandlingen af anæmi
CN100391474C (zh) * 2006-06-13 2008-06-04 卢建军 用于治疗血小板减少的注射用药物
CA2670345A1 (en) 2006-12-01 2008-06-12 Stategics, Inc. Thrombopoietin mimetics
US8383124B2 (en) 2008-03-12 2013-02-26 Children's Hospital Medical Center Mobilization of hematopoietic stem cells
ES2729622T3 (es) 2008-06-03 2019-11-05 Janssen Pharmaceutica Nv Péptido mimético de TPO para prevenir el desorden hematológico asociado al tratamiento contra el cáncer
JP2012250880A (ja) 2011-06-03 2012-12-20 Semiconductor Energy Lab Co Ltd グラフェン、蓄電装置および電気機器
US20140047572A1 (en) 2012-08-13 2014-02-13 University Of Rochester Thrombopoietin mimetics for the treatment of radiation or chemical induced bone marrow injury
US20140051631A1 (en) 2012-08-17 2014-02-20 Francoise Porteu Pharmaceutical composition comprising tpo or an agonist of the tpo receptor
WO2020154637A1 (en) 2019-01-25 2020-07-30 Janssen Pharmaceutica Nv Methods of enhancing protection against organ and vascular injury, hematopoietic recovery and survival in response to total body radiation/chemical exposure
MX2021008943A (es) 2019-01-25 2021-11-04 Janssen Pharmaceutica Nv Metodos para mitigar la lesion hepatica y promover la hipertrofia hepatica, la regeneracion e injerto celular en conjunto con tratamientos de radiacion y/o radiomimeticos.

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001505898A (ja) 1996-12-11 2001-05-08 グラクソ、グループ、リミテッド レセプターに結合するペプチドおよび化合物
JP2007504132A (ja) 2003-08-28 2007-03-01 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド 受容体に結合するペプチドおよび化合物
US20080119384A1 (en) 2004-08-16 2008-05-22 Yurkow Edward J Use of TPO peptide compounds and pharmaceutical compostions in the treatment of anemia
WO2007087428A2 (en) 2006-01-25 2007-08-02 Amgen Inc. Thrombopoietic compounds
JP2012518408A (ja) 2009-02-24 2012-08-16 アレクシオン ファーマシューティカルズ， インコーポレイテッド 治療用ｔｐｏ／ｅｐｏ模倣ペプチドを含む抗体
JP2014097958A (ja) 2012-11-15 2014-05-29 Hirosaki Univ 放射線被ばく治療剤及び放射線被ばく治療方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Fang Chen et al.，Effect of radiation-induced endothelial cell injury on platelet regeneration by megakaryocytes，Journal of Radiation Research，2017年04月11日，Vol.58 No.4，456-463

Also Published As

Publication number Publication date
AU2018306329A8 (en) 2025-02-20
WO2019023418A1 (en) 2019-01-31
AU2018306329B2 (en) 2024-09-19
CN111432845B (zh) 2024-02-06
KR20200059213A (ko) 2020-05-28
US12251424B2 (en) 2025-03-18
KR102688415B1 (ko) 2024-07-24
CN111432845A (zh) 2020-07-17
JP2020528903A (ja) 2020-10-01
US20200164039A1 (en) 2020-05-28
BR112020001367A2 (pt) 2020-08-11
EP3658191A1 (en) 2020-06-03
AU2018306329A1 (en) 2020-02-13
PH12020500166A1 (en) 2020-09-14
AU2018306329B8 (en) 2025-02-20
IL272213A (en) 2020-03-31
CA3070442A1 (en) 2019-01-31

Similar Documents

Publication Publication Date Title
JP7481252B2 (ja) 標的放射線治療誘発性血管完全性を保護する方法
Alphandéry Glioblastoma treatments: an account of recent industrial developments
Chanda et al. Gold nanoparticle based X-ray contrast agent for tumor imaging in mice and dog: a potential nanoplatform for computer tomography theranostics
Palmowski et al. Molecular ultrasound imaging of early vascular response in prostate tumors irradiated with carbon ions
US20220347212A1 (en) Prophylactic and therapeutic use of mitochondria and combined mitochondrial agents
US20220168392A1 (en) Methods of Enhancing Protection Against Organ and Vascular Injury, Hematopoietic Recovery and Survival in Response to Total Body Radiation/Chemical Exposure
JP2022523663A5 (https=)
ES2854298T3 (es) Tratamiento con SYD985 de pacientes con cáncer resistentes a T-DM1
US20070010438A1 (en) Tumor treatment using beta-sheet peptides and radiotherapy
JP2025037963A (ja) 放射性微粒子の腫瘍内沈着によるがんの処置方法
HK40033362A (en) Methods of protecting vascular integrity induced by targeted radiation therapy
US20220047643A1 (en) Fibroblasts and microvesicles thereof for reduction of toxicity associated with cancer immunotherapy
JP2016512221A (ja) リンパ節検出のための低浸透圧溶液
US20230064292A1 (en) Methods of treating psma-positive cancer using radionuclide therapy
EP0692259A2 (en) Use of HCG-specific antibody for the treatment of brain neoplasms
JP2025517424A (ja) 放射線への曝露及び／又は放射線若しくは放射線模倣治療と併用して肺損傷を緩和する方法
Jensen et al. Clinical Update: treatment of glioblastoma multiforme with radiolabeled antibodies that target tumor necrosis
Nicholson et al. 576: Combination Antiangiogenic and Androgen Deprivation Therapy for Prostate Cancer: A Promising Therapeutic Approach
Werahera et al. 575: Proliferative Tumor Doubling Times of Prostatic Carcinoma Measured by in Vivo Bromodeoxyuridine (BRDU) Labeling and Flow Cytometric Analysis
Miyagi et al. 574: Cellular Interaction Between Prostate Cancer and Bone Stroma: Effects of Radiation on the Growth and Colonization of Human Prostate Cancer Cells in Bone
Gan et al. A Phase 1 and Biodistribution Study of ABT-806i, An Indium-111 Radiolabeled Conjugate of the Tumor-Specific Anti-EGFR Antibody ABT-806
US20060210572A1 (en) Treatment of lymphatic metastatic cancerous lesions
Corn Highlights from the 46th Annual Meeting of the American Society for Therapeutic Radiology and Oncology (ASTRO)
CA2494209A1 (en) Radiosensitizer formulations and methods for use

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210709

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210709

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20220527

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220607

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220907

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221107

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230110

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230407

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230609

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230707

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230926

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20240111

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240124

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20240202

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240402

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240425

R150 Certificate of patent or registration of utility model

Ref document number: 7481252

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150